TABLE OF CONTENTS
Volume 21, Issue 3 (March 2007)
Editorials
Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe—Impact of cost considerations
A Gratwohl, H Baldomero, A Schwendener, M Gratwohl, A Urbano-Ispizua and K Frauendorfer For the Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and the European Group for Blood and Marrow Transplantation (EBMT) (JACIE)
Leukemia 21: 383-386; doi:10.1038/sj.leu.2404509
Do affluent societies have the only options for the best therapy?
J L Gajewski and P Robinson
Leukemia 21: 387-388; doi:10.1038/sj.leu.2404534
Review
The pathogenesis of MALT lymphomas: where do we stand?
X Sagaert, C De Wolf-Peeters, H Noels and M Baens
Leukemia 21: 389-396; advance online publication, January 18, 2007; doi:10.1038/sj.leu.2404517
Leading Article
FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells
B Crescenzi, A Chase, R La Starza, D Beacci, V Rosti, A Gallì, G Specchia, M F Martelli, P Vandenberghe, J Cools, A V Jones, N C P Cross, P Marynen and C Mecucci
Leukemia 21: 397-402; advance online publication, January 11, 2007; doi:10.1038/sj.leu.2404510
Original Articles
Molecular Targets for Therapy
Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD
M Okamoto, F Hayakawa, Y Miyata, K Watamoto, N Emi, A Abe, H Kiyoi, M Towatari and T Naoe
Leukemia 21: 403-410; advance online publication, January 18, 2007; doi:10.1038/sj.leu.2404547
Leukemia targeting ligands isolated from phage display peptide libraries
S Jäger, A Jahnke, T Wilmes, S Adebahr, F-N Vögtle, E deLima-Hahn, D Pfeifer, T Berg, M Lübbert and M Trepel
Leukemia 21: 411-420; advance online publication, January 25, 2007; doi:10.1038/sj.leu.2404548
Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines
D J Barnes, S De, P van Hensbergen, È Moravcsik and J V Melo
Leukemia 21: 421-426; advance online publication, January 25, 2007; doi:10.1038/sj.leu.2404533
Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts
P L Tazzari, A Cappellini, F Ricci, C Evangelisti, V Papa, T Grafone, G Martinelli, R Conte, L Cocco, J A McCubrey and A M Martelli
Leukemia 21: 427-438; advance online publication, January 11, 2007; doi:10.1038/sj.leu.2404523
Therapy
Antitumor activity of sorafenib in FLT3-driven leukemic cells
D Auclair, D Miller, V Yatsula, W Pickett, C Carter, Y Chang, X Zhang, D Wilkie, A Burd, H Shi, S Rocks, R Gedrich, L Abriola, H Vasavada, M Lynch, J Dumas, P A Trail and S M Wilhelm
Leukemia 21: 439-445; advance online publication, January 4, 2007; doi:10.1038/sj.leu.2404508
Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention
J Esteve, L Escoda, G Martín, V Rubio, J Díaz-Mediavilla, M González, C Rivas, C Álvarez, J D González San Miguel, S Brunet, J F Tomás, M Tormo, M J Sayas, P Sánchez Godoy, D Colomer, P Bolufer and M A Sanz on behalf of the Spanish Cooperative Group PETHEMA
Leukemia 21: 446-452; advance online publication, January 4, 2007; doi:10.1038/sj.leu.2404501
Effect of priming with granulocyte–macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group
X Thomas, E Raffoux, S de Botton, C Pautas, P Arnaud, T de Revel, O Reman, C Terré, B Corront, C Gardin, Q-H Le, B Quesnel, C Cordonnier, J-H Bourhis, M Elhamri, P Fenaux, C Preudhomme, M Michallet, S Castaigne and H Dombret
Leukemia 21: 453-461; advance online publication, January 25, 2007; doi:10.1038/sj.leu.2404521
Acute Leukemias
NOTCH1-induced T-cell leukemia in transgenic zebrafish
J Chen, C Jette, J P Kanki, J C Aster, A T Look and J D Griffin
Leukemia 21: 462-471; advance online publication, January 25, 2007; doi:10.1038/sj.leu.2404546
Myelodyspasias
Increased frequencies of CD4+CD25high Tregs correlate with disease relapse after allogeneic stem cell transplantation for chronic myeloid leukemia FREE
E Nadal, M Garin, J Kaeda, J Apperley, R Lechler and F Dazzi
Leukemia 21: 472-479; advance online publication, January 11, 2007; doi:10.1038/sj.leu.2404522
Levels of soluble HLA-I and 
2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy
M Albitar, M Johnson, K A Do, A Day, I Jilani, S Pierce, E Estey, H Kantarjian, M Keating, S Verstovsek, S O'Brien and F J Giles
Leukemia 21: 480-488; advance online publication, January 11, 2007; doi:10.1038/sj.leu.2404506
Chronic Myeloproliferative Disorders
Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib
D W Sherbenou, M J Wong, A Humayun, L S McGreevey, P Harrell, R Yang, M Mauro, M C Heinrich, R D Press, B J Druker and M W Deininger
Leukemia 21: 489-493; advance online publication, January 25, 2007; doi:10.1038/sj.leu.2404554
Molecular signature of CD34+ hematopoietic stem and progenitor cells of patients with CML in chronic phase FREE
E Diaz-Blanco, I Bruns, F Neumann, J C Fischer, T Graef, M Rosskopf, B Brors, S Pechtel, S Bork, A Koch, A Baer, U-P Rohr, G Kobbe, A von Haeseler, N Gattermann, R Haas and R Kronenwett
Leukemia 21: 494-504; advance online publication, January 25, 2007; doi:10.1038/sj.leu.2404549
Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders
E Jost, N do Ó, E Dahl, C E Maintz, P Jousten, L Habets, S Wilop, J G Herman, R Osieka and O Galm
Leukemia 21: 505-510; advance online publication, January 18, 2007; doi:10.1038/sj.leu.2404513
Chronic Lympthocytic Leukemia
Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody)
C Karlsson, L Hansson, F Celsing and J Lundin
Leukemia 21: 511-514; advance online publication, January 11, 2007; doi:10.1038/sj.leu.2404512
Lymphoma
Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas
P Bertrand, C Bastard, C Maingonnat, F Jardin, C Maisonneuve, M-N Courel, P Ruminy, J-M Picquenot and H Tilly
Leukemia 21: 515-523; advance online publication, January 18, 2007; doi:10.1038/sj.leu.2404529
Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma
O Weigert, A Pastore, M Rieken, N Lang, W Hiddemann and M Dreyling
Leukemia 21: 524-528; advance online publication, February 1, 2007; doi:10.1038/sj.leu.2404511
Myeloma
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy FREE
A K Stewart, P L Bergsagel, P R Greipp, A Dispenzieri, M A Gertz, S R Hayman, S Kumar, M Q Lacy, J A Lust, S J Russell, T E Witzig, S R Zeldenrust, D Dingli, C B Reeder, V Roy, R A Kyle, S V Rajkumar and R Fonseca
Leukemia 21: 529-534; advance online publication, January 18, 2007; doi:10.1038/sj.leu.2404516
Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of -catenin/TCF pathway
H Yasui, T Hideshima, H Ikeda, E M Ocio, T Kiziltepe, S Vallet, Y Okawa, P Neri, K Sukhdeo, K Podar, D Chauhan, P G Richardson, N Raje, D R Carrasco and K C Anderson
Leukemia 21: 535-540; advance online publication, February 1, 2007; doi:10.1038/sj.leu.2404561
Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals FREE
N C Gutiérrez, E M Ocio, J de las Rivas, P Maiso, M Delgado, E Fermiñán, M J Arcos, M L Sánchez, J M Hernández and J F San Miguel
Leukemia 21: 541-549; advance online publication, January 25, 2007; doi:10.1038/sj.leu.2404520
Letters to the Editor
Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML
K Summers, J Stevens, I Kakkas, M Smith, L L Smith, F MacDougall, J Cavenagh, D Bonnet, B D Young, T A Lister and J Fitzgibbon
Leukemia 21: 550-551; advance online publication, January 4, 2007; doi:10.1038/sj.leu.2404514
Reply to 'Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML' by Summers et al.
C G Nyvold, H B Ommen, M Østergaard and P Hokland
Leukemia 21: 552; advance online publication, January 4, 2007; doi:10.1038/sj.leu.2404515
Risk factors of central venous lines-related thrombosis in children with acute lymphoblastic leukemia during induction therapy: a prospective study
L Farinasso, N Bertorello, L Garbarini, T M Gajno, E Barisone, L Artesani, A Valori, M Giacchino, G Pastore and P Saracco
Leukemia 21: 552-556; advance online publication, February 1, 2007; doi:10.1038/sj.leu.2404560
Second allogeneic hematopoietic stem cell transplantation (HSCT) results in outcome similar to that of first HSCT for patients with juvenile myelomonocytic leukemia
A Yoshimi, M Mohamed, M Bierings, C Urban, E Korthof, M Zecca, K-W Sykora, U Duffner, M Trebo, S Matthes-Martin, P Sedlacek, T Klingebiel, P Lang, M Führer, A Claviez, W Wössmann, A Pession, J Arvidson, A S O'Marcaigh, M M van den Heuvel-Eibrink, J Starý, H Hasle, P Nöllke, F Locatelli and C M Niemeyer On behalf of the European Working Group of MDS in Childhood (EWOG-MDS)
Leukemia 21: 556-560; advance online publication, February 1, 2007; doi:10.1038/sj.leu.2404537
Thymidine kinase 1 – A prognostic and diagnostic indicator in ALL and AML patients
K L O'Neill, F Zhang, H Li, D G Fuja and B K Murray
Leukemia 21: 560-563; advance online publication, January 25, 2007; doi:10.1038/sj.leu.2404536
Phosphoproteomic analysis identifies the M0-91 cell line as a cellular model for the study of TEL-TRKC fusion-associated leukemia
T-L Gu, L Popova, C Reeves, J Nardone, J MacNeill, J Rush, S D Nimer and R D Polakiewicz
Leukemia 21: 563-566; advance online publication, January 25, 2007; doi:10.1038/sj.leu.2404555
CD200 as a prognostic factor in acute myeloid leukaemia
A Tonks, R Hills, P White, B Rosie, K I Mills, A K Burnett and R L Darley
Leukemia 21: 566-568; advance online publication, January 25, 2007; doi:10.1038/sj.leu.2404559
Infusion of allogeneic-related HLA mismatched mesenchymal stem cells for the treatment of incomplete engraftment following autologous haematopoietic stem cell transplantation
L Fouillard, A Chapel, D Bories, S Bouchet, J-M Costa, H Rouard, P Hervé, P Gourmelon, D Thierry, M Lopez and N C Gorin
Leukemia 21: 568-570; advance online publication, January 25, 2007; doi:10.1038/sj.leu.2404550
Oligonucleotide array-CGH reveals cryptic gene copy number alterations in karyotypically normal acute myeloid leukemia
A Tyybäkinoja, E Elonen, K Piippo, K Porkka and S Knuutila
Leukemia 21: 571-574; advance online publication, February 1, 2007; doi:10.1038/sj.leu.2404543
JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults
H Kiyoi, S Yamaji, S Kojima and T Naoe
Leukemia 21: 574-576; advance online publication, January 25, 2007; doi:10.1038/sj.leu.2404527
Myelofibrosis with a novel translocation, t(1;3)(q31;q23), and response to imatinib mesylate
K Yalamanchili, D Liu and K Seiter
Leukemia 21: 577-578; advance online publication, January 18, 2007; doi:10.1038/sj.leu.2404552
Diagnosis of invasive aspergillosis by tracking Aspergillus-specific T cells in hematologic patients with pulmonary infiltrates
L Potenza, P Barozzi, D Vallerini, R Bosco, C Quadrelli, L Mediani, M Morselli, F Forghieri, F Volzone, M Codeluppi, G Rossi, G Tazzioli, C Venturelli, G Torelli and M Luppi
Leukemia 21: 578-581; advance online publication, January 11, 2007; doi:10.1038/sj.leu.2404504
Clinical significance of TP53 mutation in myeloma
W J Chng, T Price-Troska, N Gonzalez-Paz, S Van Wier, S Jacobus, E Blood, K Henderson, M Oken, B Van Ness, P Greipp, S V Rajkumar and R Fonseca
Leukemia 21: 582-584; advance online publication, January 11, 2007; doi:10.1038/sj.leu.2404524
Deletion of 11q23 is a highly specific nonrandom secondary genetic abnormality of ETV6/RUNX1-rearranged childhood acute lymphoblastic leukemia
A Attarbaschi, G Mann, S Strehl, M König, M Steiner, V Jeitler, Th Lion, M N Dworzak, H Gadner and O A Haas on behalf of the Austrian Berlin-Frankfurt–Münster (BFM) Cooperative Study Group
Leukemia 21: 584-586; advance online publication, January 11, 2007; doi:10.1038/sj.leu.2404507
Treatment of deletion 5q acute myeloid leukemia with lenalidomide
J E Lancet, A F List and L C Moscinski
Leukemia 21: 586-588; advance online publication, January 18, 2007; doi:10.1038/sj.leu.2404526
Spliced MLL fusions: a novel mechanism to generate functional chimeric MLL-MLLT1 transcripts in t(11;19)(q23;p13.3) leukemia
C Meyer, T Burmeister, S Strehl, B Schneider, D Hubert, O Zach, O Haas, T Klingebiel, T Dingermann and R Marschalek
Leukemia 21: 588-590; advance online publication, January 25, 2007; doi:10.1038/sj.leu.2404542
